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Abstract
A multicentre, case–control study was conducted to assess risk factors and patient outcomes of bacteraemia caused by Enterobacteria-
ceae producing extended-spectrum b-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemases (KPCs). One hundred and ﬁve and
20 patients with bacteraemia caused by ESBL-producing and KPC-producing organisms were matched to controls who had bacteraemia
caused by non-ESBL/KPC-producing organisms, respectively. Independent risk factors for ESBL production included admission from a
nursing home (OR 4.64; 95% CI 2.64–8.16), chronic renal failure (OR 2.09; 95% CI 1.11–3.92), the presence of a gastrostomy tube
(OR 3.36; 95% CI 1.38–8.18), length of hospital stay before infection (OR 1.02; 95% CI 1.01–1.03), transplant receipt (OR 2.48;
95% CI 1.24–4.95), and receipt of antibiotics with Gram-negative activity in the preceding 30 days (OR 1.76; 95% CI 1.00–3.08).
Twenty-eight-day crude mortality rates for patients infected with ESBL-producing or KPC-producing organisms and controls were
29.1% (34/117) and 19.5% (53/272), respectively (OR 1.70; 95% CI 1.04–2.80). On multivariate analysis, inadequate empirical therapy
(OR 2.26; 95% CI 1.18–4.34), onset of bacteraemia while in the intensive-care unit (OR 2.74; 95% CI 1.47–5.11), Apache II score
(OR 1.17; 95% CI 1.12–1.23) and malignancy (OR 2.66; 95% CI 1.31–5.41) were independent risk factors for mortality. CTX-M was the
most common ESBL type in Escherichia coli, whereas SHV predominated in Klebsiella spp. and Enterobacter spp.
Keywords: bacteraemia, carbapenem, Enterobacteriaceae, extended-spectrum b-lactamase, Klebsiella pneumoniae carbapenemase
Original Submission: 2 May 2011; Revised Submission: 26 July 2011; Accepted: 21 August 2011
Editor: R. Canto´n
Article published online: 26 August 2011
Clin Microbiol Infect 2012; 18: 887–893
10.1111/j.1469-0691.2011.03658.x
Corresponding author: Y. Doi, Division of Infectious Diseases,
Department of Medicine, University of Pittsburgh Medical Center,
S829 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA
E-mail: yod4@pitt.edu
Introduction
Extended-spectrum b-lactamases (ESBLs) are now well rec-
ognized as a major cause of cephalosporin resistance
among Enterobacteriaceae [1,2]. Two important changes in
the epidemiology of ESBLs have occurred in the last dec-
ade. One is the rapid global dissemination of Escherichia coli
producing CTX-M-type ESBLs. CTX-M has now become
the predominant ESBL type in Europe, Canada, South
America, and Asia [3]. Several recent studies suggest that it
is ﬁnally replacing classic TEM-type and SHV-type ESBLs in
the USA as well [4–6]. The other change is the advent of
Klebsiella pneumoniae carbapenemases (KPCs). Initially caus-
ing outbreaks in hospitals on the east coast of the USA,
KPC-producing K. pneumoniae has now spread worldwide
[7]. The aims of the present study were to investigate the
risk factors, clinical outcome and predictors of mortality in
a contemporary cohort of patients with bacteraemia caused
by ESBL-producing and KPC-producing Enterobacteriaceae in
the USA.
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Patients and Methods
Study design and patients
This multicentre, retrospective case–control study was con-
ducted at three medical centres in the northeastern USA
(New York, Massachusetts, and Pennsylvania) between 2005
and 2008. Patients with blood cultures growing E. coli,
K. pneumoniae, Klebsiella oxytoca, Enterobacter cloacae and
Enterobacter aerogenes were included. The two case groups
consisted of those caused by ESBL-producing and KPC-pro-
ducing organisms. Controls were selected so that each
study site and species occurred in similar proportions in
both cases and controls, with a ratio of three controls per
case. The entire control group was used for the ESBL analy-
sis, whereas only cases caused by K. pneumoniae were
included in the KPC analysis, as all KPC-producing organ-
isms belonged to this species. Only the ﬁrst episode of
bacteraemia was included for each patient. The study was
approved by the Institutional Review Board at each partici-
pating site.
Risk factor analyses
The variables reviewed for risk factor analyses included
demographic data, admission from a nursing home, prior use
of antibiotics with Gram-negative activity in the preceding
30 days, presence of tracheostomy tube, gastrostomy tube,
intravenous line or urinary catheter at the time of infection,
prior hospitalization, length of hospital stay before the onset
of bacteraemia, intensive-care unit (ICU) admission, surgery,
outpatient intravenous therapy or dialysis in the preceding
1 year, diabetes, the presence of chronic renal failure, liver
disease, chronic obstructive pulmonary disease, cardiovascu-
lar disease, peripheral vascular disease, cerebrovascular dis-
ease, peptic ulcer disease, malignancy and history of organ
transplant. The Apache II score was also collected and
included in the univariate analysis, but was not included in
the multivariate analysis because it could not be deﬁned for
>10% of the cases. Immunocompromised state was deﬁned
as the presence of diabetes mellitus, neutropenia, human
immunodeﬁciency virus infection, or receipt of steroids or
other immunosuppressive agents in the 30 days prior to
infection.
Predictors of mortality
The primary outcome measure was death within 28 days
from the onset of bacteraemia. Predictors of 28-day mortality
were analysed for the whole study population, as well as
within the ESBL or KPC cases and the controls separately.
Patients for whom 28-day status was unknown were excluded
from the mortality analyses (n = 61). The parameters
reviewed in addition to those used for risk factor analyses
were inadequate empirical therapy, deﬁned as receipt of
empirical antibiotics with no in vitro activity against the infect-
ing organism, ICU stay at the time of infection, source of bac-
teraemia, and Apache II score.
Microbiological methods
All E. coli and Klebsiella isolates that were reported as ESBL
producers were subjected to PCR analyses to identify the
presence of TEM-type, SHV-type and CTX-M-type b-lactam-
ase genes [8]. Positive PCR results were followed by
sequencing of the ampliﬁed products. For Enterobacter spp.,
all piperacillin-resistant or ceftriaxone-non-susceptible Ente-
robacter isolates were subjected to PCR analyses for the
ESBL genes and sequencing [9]. For all species, ceftriaxone-
non-susceptible isolates (corresponding to MICs ‡16 mg/L)
underwent PCR analysis for detection of the KPC gene [10].
Statistical analyses
Statistical analyses were performed with SAS version 9.2
(SAS Institute, Cary, NC, USA). For univariate analysis of risk
factors and predictors of mortality, univariate logistic regres-
sion was performed. To identify independent risk factors and
predictors of mortality, variables with a p-value £0.15 on
univariate analysis were included in a stepwise conditional
multivariate logistic regression model. All p-values were two-
tailed, and a p-value £0.05 was considered to be statistically
signiﬁcant.
Results
Demographics of the cohorts
A total of 450 patients with bacteraemia caused by Enterobac-
teriaceae (E. coli, Klebsiella spp., and Enterobacter spp.) were
included. One hundred and twenty-ﬁve bacteraemia cases
were caused by ESBL-producing or KPC-producing organ-
isms, including E. coli (n = 32), Klebsiella spp. (n = 76), and
Enterobacter spp. (n = 17). Of these, 20 cases were caused by
KPC-producing K. pneumoniae, all of which were from the
study site in New York City. The remaining 105 cases consti-
tuted the ESBL group. A total of 325 control cases were
selected for analysis of the ESBL group. For analysis of the
KPC group, K. pneumoniae cases from this control group
were assigned (n = 176). The characteristics of these patients
relative to ESBL and KPC status are shown in Tables 1 and 2,
respectively. In the analysis of the ESBL and control groups,
there was no signiﬁcant difference in the proportion of
patients >60 years of age, sex or race between the cases and
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controls (Table 1). In the analysis of the KPC and control
groups, there were signiﬁcantly fewer Caucasian patients in
the KPC group, reﬂecting the predominance of African
American patients at the study site in New York City, where
all of the KPC cases were identiﬁed (Table 2).
Risk factors for ESBL production
Independent risk factors for bacteraemia caused by ESBL-
producing organisms, after adjustment for potential con-
founding variables, included admission from a nursing home
(OR 4.64; 95% CI 2.64–8.16, p <0.0001), chronic renal fail-
ure (OR 2.09; 95% CI 1.11–3.92, p 0.0223), the presence of
a gastrostomy tube (OR 3.36; 95% CI 1.38–8.18, p 0.0076),
length of hospital stay before infection (OR 1.02;
95% CI 1.01–1.03, p 0.0015), history of transplant (OR 2.48;
95% CI 1.24–4.95, p 0.0103), and receipt of antibiotics with
Gram-negative activity in the preceding 30 days (OR 1.76;
95% CI 1.00–3.08, p 0.0491) (Table 1).
For further characterization of the association between
prior antibiotic exposure and ESBL-producing organisms, the
antibiotics were divided into classes and assessed for their
association. We observed that prior use of cefepime and car-
bapenems was signiﬁcantly associated with infection with an
ESBL-producing organism in the univariate analysis, but the
signiﬁcance did not remain in the multivariate analysis
(Table 1).
Risk factors for KPC production
Owing to the relatively small number of KPC cases, multivar-
iate analysis was deferred for this comparison. In the univari-
ate analysis, signiﬁcant risk factors were largely consistent
with those observed with the ESBL group, with the excep-
tion of surgery in the past year (Table 2). Regarding the indi-
vidual antibiotic classes, receipt of carbapenems, cefepime or
ceftriaxone in the prior 30 days was associated with infection
with a KPC-producing organism.
TABLE 1. Demographics and risk factors of cases with extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae
Demographics/risk factors




group % OR 95% CI p-value OR 95% CI p-value
Apache II score 15.5a 0–49b 13a 1–45b 1.04 1.01–1.07 0.01 – – –
Male 54 51.43 167 51.38 1.00 0.65–1.56 0.99 – – –
Age >60 years 51 48.57 174 53.70 0.81 0.52–1.26 0.36 – – –
Immunocompromised 63 60.00 160 49.23 1.55 0.99–2.42 0.06 – – –
Caucasian 54 66.67 173 66.03 1.03 0.61–1.74 0.92 – – –
Hispanic 5 6.17 27 10.31 0.57 0.21–1.54 0.27 – – –
Admitted from nursing home 44 43.14 41 12.65 5.24 3.14–8.73 <0.0001 4.64 2.64–8.16 <0.0001
Number of days hospitalized before infection 5a 0–328b 1a 0–141b 1.02 1.01–1.03 <0.0001 1.02 1.01–1.03 0.0015
Any hospitalization in past year 84 80.00 242 74.46 1.37 0.80–2.35 0.25 – – –
Any ICU admission in past year 44 41.90 95 29.23 1.75 1.11–2.75 0.02 – – –
Any surgery in past year 47 44.76 113 34.77 1.52 0.97–2.38 0.07 – – –
Dialysis in past year 19 18.10 29 8.92 2.26 1.21–4.22 0.01 – – –
Outpatient intravenous therapy in past year 15 14.29 24 7.38 2.09 1.05–4.15 0.04 – – –
Prior surgery within 30 days 15 14.29 53 16.31 0.86 0.46–1.59 0.62 – – –
Antibiotics in 30 days prior to enrolment 48 47.06 76 23.38 2.91 1.83–4.64 <0.0001 1.76 1.00–3.08 0.0491
Carbapenemc 8 7.62 8 2.46 3.27 1.20–8.94 0.02 – – –
Ampicillin–sulbactam 6 5.71 15 4.62 1.25 0.47–3.32 0.65 – – –
Fluoroquinoloned 12 11.43 28 8.62 1.37 0.67–2.80 0.39 – – –
Cefepime 18 17.14 17 5.23 3.75 1.85–7.58 0.0002 – – –
Ceftriaxone 4 3.81 4 1.23 3.18 0.78–12.94 0.11 – – –
Piperacillin–tazobactam 8 7.62 17 5.23 1.49 0.63–3.57 0.37 – – –
Chronic renal failure 28 26.67 41 12.62 2.52 1.46–4.33 0.0008 2.09 1.11–3.92 0.0223
Diabetes 40 38.10 79 24.31 1.92 1.20–3.06 0.006 – – –
Chronic obstructive pulmonary disease 11 10.48 45 13.85 0.73 0.36–1.47 0.37 – – –
Cardiovascular disease 29 27.62 77 23.69 1.23 0.75–2.02 0.42 – – –
Peripheral vascular disease 4 3.81 8 2.46 1.57 0.46–5.32 0.47 – – –
Cerebrovascular disease 9 8.57 27 8.31 1.03 0.47–2.28 0.93 – – –
Peptic ulcer disease 3 2.86 13 4.00 0.71 0.20–2.53 0.59 – – –
Liver disease 17 16.19 35 10.77 1.60 0.86–3.00 0.14 – – –
Malignancy 14 13.33 61 18.77 0.67 0.36–1.25 0.20 – – –
Solid organ malignancy 10 9.52 53 16.31 0.54 0.26–1.10 0.09 – – –
Transplant 23 21.90 34 10.46 2.40 1.34–4.30 0.003 2.48 1.24–4.95 0.0103
Tracheostomy tube at enrolment 26 24.76 29 8.92 3.36 1.87–6.03 <0.0001 – – –
Gastrostomy tube at enrolment 17 16.19 12 3.69 5.04 2.32–10.95 <0.0001 3.36 1.38–8.18 0.0076
Indwelling urinary catheter at enrolment 26 24.76 51 15.69 1.77 1.04–3.02 0.04 – – –
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Empirical therapy
Of the 450 patients included in the study, 329 (73.1%)
received appropriate empirical antibiotic therapy. Of the 125
cases with ESBL-producing or KPC-producing organisms, 44
(35.2%) received appropriate empirical therapy, whereas 285
of 325 (87.7%) patients received appropriate therapy in the
control group. Patients with bacteraemia caused by an ESBL-
producing or KPC-producing organism were signiﬁcantly
more likely to receive inappropriate empirical antibiotic ther-
apy than the controls (OR 13.12; 95% CI 8.00–21.50;
p <0.001).
Clinical outcome
For cases whose clinical outcome 28 days after enrolment
was available (n = 389), 28-day crude mortality rates for
patients infected with ESBL-producing or KPC-producing
organisms and controls were 29.1% (34/117) and 19.5% (53/
272), respectively (OR 1.70; 95% CI 1.03–2.79; p 0.04).
When cases with KPC-producing and ESBL-producing
K. pneumoniae were compared, the 28-day crude mortality
rate was 47.4% (9/19) for cases with KPC-producing K. pneu-
moniae as opposed to 27.5% (14/51) for cases with ESBL-pro-
ducing K. pneumoniae (OR 2.38; 95% CI 0.80–7.08; p 0.12).
Predictors of mortality
Predictors of mortality were ﬁrst assessed for the whole
study population. The results from univariate and multivari-
ate analyses are shown in Table 3. Independent predictors
included inadequate empirical therapy (OR 2.26;
95% CI 1.18–4.34; p 0.01), bacteraemia while in the ICU
(OR 2.74; 95% CI 1.47–5.11; p 0.002), Apache II score
(OR 1.17; 95% CI 1.12–1.23; p <0.001), and malignancy
(OR 2.66; 95% CI 1.31–5.41; p 0.007) (Table 3). Production
of ESBL or KPC was a signiﬁcant predictor of mortality
in the univariate analysis but was not a predictor after
adjustment for other confounding variables in the multivari-
ate analysis.
The predictors of mortality were then assessed for the
ESBL group. Inadequate empirical therapy (OR 6.30;
95% CI 1.64–24.3; p 0.007) and Apache II score (OR 1.14;





group % OR 95% CI p-value
Apache II score 21a 3–44b 14a 1–45b 1.11 1.05–1.17 0.0001
Male 8 40.00 92 52.27 0.61 0.24–1.56 0.30
Age >60 years 12 60.00 95 54.29 1.26 0.49–3.24 0.63
Immunocompromised 13 65.00 93 52.84 1.66 0.63–4.35 0.30
Caucasian 4 21.05 96 67.61 0.13 0.04–0.41 0.0005
Hispanic 3 15.79 13 9.15 1.86 0.48–7.24 0.37
Admitted from nursing home 6 30.00 28 16.00 2.25 0.80–6.35 0.13
Number of days hospitalized before infection 20a 0–323b 1a 0–141b 1.03 1.01–1.05 0.0006
Any hospitalization in past year 16 80.00 141 80.11 0.99 0.31–3.16 0.99
Any ICU admission in past year 9 45.00 54 30.68 1.85 0.72–4.72 0.20
Any surgery in past year 13 65.00 64 36.36 3.25 1.23–8.56 0.02
Dialysis in past year 1 5.00 8 4.55 1.11 0.13–9.32 0.93
Outpatient intravenous therapy in past year 3 15.00 16 9.09 1.76 0.47–6.68 0.40
Prior surgery within 30 days 3 15.00 26 14.77 1.02 0.28–3.72 0.98
Antibiotics in 30 days prior to enrolment 17 85.00 40 22.73 19.3 5.37–69.07 <0.0001
Carbapenemc 5 25.00 4 2.27 14.3 3.48–59.10 0.0002
Ampicillin–sulbactam 2 10.00 11 6.25 1.67 0.34–8.12 0.53
Fluoroquinoloned 2 10.00 13 7.39 1.39 0.29–6.67 0.68
Cefepime 9 45.00 8 4.55 17.2 5.54–53.23 <0.0001
Ceftriaxone 3 15.00 2 1.14 15.3 2.40–98.27 0.004
Piperacillin–tazobactam 0 0.00 7 3.98 0.90 0.00–6.33 0.93
Chronic renal failure 6 30.00 21 11.93 3.16 1.10–9.13 0.03
Diabetes 6 30.00 41 23.30 1.41 0.51–3.91 0.51
Chronic obstructive pulmonary disease 4 20.00 29 16.48 1.27 0.40–4.07 0.69
Cardiovascular disease 5 25.00 41 23.30 1.10 0.38–3.20 0.86
Peripheral vascular disease 1 5.00 3 1.70 3.04 0.30–30.65 0.35
Cerebrovascular disease 3 15.00 13 7.39 2.21 0.57–8.55 0.25
Peptic ulcer disease 0 0.00 9 5.11 0.68 0–4.60 0.74
Liver disease 2 10.00 17 9.66 1.04 0.22–4.87 0.96
Malignancy 8 40.00 41 23.30 2.20 0.84–5.74 0.11
Solid organ malignancy 7 35.00 36 20.45 2.09 0.78–5.63 0.14
Transplant 1 5.00 17 9.66 0.49 0.06–3.91 0.50
Tracheostomy tube at enrolment 8 40.00 17 9.66 6.24 2.24–17.38 0.0005
Gastrostomy tube at enrolment 9 45.00 7 3.98 19.8 6.19–63.06 <0.0001
Indwelling urinary catheter at enrolment 5 25.00 25 14.20 2.01 0.67–6.03 0.21
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95% CI 1.06–1.24; p 0.0009) were independent predictors of
mortality. However, when the analysis was performed for
the control group, inadequate empirical therapy, which 11%
of the patients received, was no longer a predictor (p 0.34).
Apache II score (OR 1.24; 95% CI 1.16–1.32; p <0.001),
onset of bacteraemia while in the ICU (OR 3.97;
95% CI 1.77–8.92; p <0.001) and malignancy (OR 2.62;
95% CI 1.09–6.27; p 0.03) remained as independent predic-
tors in the control group. Mortality analysis for the KPC
group was deferred because of the small number of cases.
Types of ESBL and KPC
The types of ESBL, including KPC-type b-lactamases, are
summarized in Table 4. Of 29 E. coli cases for which isolates
were available, 21 (72.4%) had CTX-M-type ESBLs, of which
11 (52%) were CTX-M-15. Only seven (24.1%) had SHV-type
or TEM-type ESBLs. For 74 Klesbiella spp. cases for which
isolates were available, 20 (27.0%) were KPC producers (all
K. pneumoniae). They were found to produce either KPC-2
(n = 8) or KPC-3 (n = 12). Of the remaining 54 ESBL-pro-
ducing, non-KPC-producing Klesbiella spp., isolates 47 (87.0%)
and 6 (11.1%) had SHV-type and CTX-M-type ESBLs, respec-
tively. For Enterobacter spp., 14 of 17 (82.4%) ESBL cases
produced SHV-type ESBLs, whereas three (17.6%) produced
CTX-M-type ESBLs.
Discussion
The emergence and spread of CTX-M-type ESBLs and
KPC-type carbapenemases are the two major developments
TABLE 3. Predictors of mortality in all patients with bacteraemia caused by Enterobacteriaceae
Predictors of mortality
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Apache II score 1.18 (1.14–1.23) <0.0001 1.2 (1.12–1.23) <0.0001
Male 1.0 (0.62–1.62) 0.99 – –
Caucasian 0.85 (0.49–1.48) 0.57 – –
Hispanic 2.0 (0.92–4.35) 0.08 – –
Age >60 years 1.6 (0.98–2.60) 0.06 – –
Immunocompromised 1.2 (0.74–1.93) 0.48 – –
Onset of bacteraemia in ICU 3.7 (2.24–6.02) <0.0001 2.7 (1.47–5.11) 0.002
Pneumonia as a source of bacteraemia 2.1 (1.05–4.29) 0.04 – –
Length of hospital stay before bacteraemia 1.0 (1.00–1.01) 0.33 – –
Admitted from nursing home 1.5 (0.87–2.68) 0.14 – –
Inadequate empirical therapy 2.5 (1.52–4.15) 0.0003 2.3 (1.18–4.34) 0.01
Production of ESBL or KPC 1.7 (1.03–2.80) 0.04 – –
Diabetes 1.0 (0.59–1.69) 0.99 – –
Chronic renal failure 1.1 (0.57–2.03) 0.82 – –
Dialysis 1.0 (0.47–2.09) 0.98 – –
Chronic obstructive pulmonary disease 1.7 (0.90–3.28) 0.10 – –
Cardiovascular disease 1.8 (1.08–3.12) 0.02 – –
Peripheral vascular disease 0.8 (0.16–3.61) 0.74 – –
Cerebrovascular disease 2.2 (1.08–4.65) 0.03 – –
Peptic ulcer disease 1.3 (0.34–5.06) 0.69 – –
Liver disease 2.2 (1.17–4.15) 0.01 – –
Malignancy 1.9 (1.12–3.37) 0.02 2.7 (1.31–5.41) 0.007
Solid organ malignancy 1.7 (0.92–3.00) 0.09 – –
Transplant 0.4 (0.15–0.88) 0.02 – –
Hospitalization in the past year 1.7 (0.90–3.17) 0.10 – –
ICU admission in the past year 1.3 (0.79–2.12) 0.30 – –
Any surgery in past year 0.8 (0.47–1.29) 0.33 – –
Outpatient intravenous therapy in past year 1.3 (0.59–2.73) 0.54 – –
Any surgery in past 30 days 1.1 (0.58–2.17) 0.73 – –
Antibiotics with Gram-negative activity in past 30 days 1.1 (0.65–1.76) 0.80 – –
Presence of tracheostomy tube 0.9 (0.48–1.81) 0.83 – –
Presence of gastrostomy tube 1.1 (0.51–2.49) 0.76 – –
Presence of indwelling urinary catheter 1.8 (1.03–3.12) 0.04 – –
Presence of vascular catheter 0.9 (0.58–1.54) 0.83 – –
ESBL, extended-spectrum b-lactamase; ICU, intensive-care unit; KPC, Klebsiella pneumoniae carbapenemase.
TABLE 4. Types of extended-spectrum b-lactamase (ESBL)
and Klebsiella pneumoniae carbapenemase (KPC) produced
by the study isolates
ESBL
Species (number of isolates)
Escherichia coli Klebsiella spp. Enterobacter spp.
CTX-M-1 group 13 2 –
CTX-M-2 group 2 3 –
CTX-M-9 group 6 1 3
SHV 6 47 14
TEM 1 – –
KPC – 20 –
Others 1a 1b –
Unknown 3 2 –
Total 32 76 17
aCMY-33 b-lactamase.
bOXY-2 b-lactamase of Klebsiella oxytoca.
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in b-lactam resistance that have taken place in the last dec-
ade. CTX-M-type ESBLs became the predominant ESBLs in
E. coli in many parts of the world by the early 2000s [3].
Although they were initially considered to be rare, recent
reports indicate that CTX-M-type ESBLs are becoming
more common in the USA as well, especially in E. coli [4].
KPC-type carbapenemases rapidly spread among K. pneumo-
niae strains, which have caused nosocomial outbreaks in
hospitals throughout the east coast of the USA [7]. Studies
from the USA that have addressed the clinical characteris-
tics of bacteraemia caused by ESBL-producing Enterobacteria-
ceae were conducted either before the advent of these
newer b-lactamases or without molecular characterization
[2,11]. The present study was thus undertaken to identify
the clinical features of bacteraemia caused by ESBL-produc-
ing and KPC-producing Enterobacteriaceae in a contemporary
cohort of patients from tertiary hospitals in the northeast-
ern USA.
Our results indicate that CTX-M-type ESBLs are now
common among bacteraemic isolates of Enterobactericeae in
this geographical area. Among E. coli, the majority had this
group of ESBLs. About half of them had CTX-M-15, which
is increasingly recognized as the most common CTX-M-
type ESBL in many parts of the world [12], but the CTX-
M-2 and CTX-M-9 groups, which are known to predomi-
nate in South America and Spain, respectively, were also
present [3]. SHV-type and TEM-type ESBLs constituted the
rest, although they were much less common than CTX-M-
type ESBLs. This trend was also reported in a recent study
of ESBL-producing E. coli conducted in Philadelphia [13].
Taking these ﬁndings together, we may assume that CTX-
M-type ESBLs are now prevalent in this species in the
northeastern USA. In Klebsiella spp. and Enterobacter spp.,
SHV was still the most common ESBL type, but CTX-M-
type ESBLs were also present in both organisms. All 20
KPC-producing organisms were from the study site in
New York City, where they are known to be endemic
[14].
The 28-day mortality rate of patients with bacteraemia
caused by organisms producing ESBL or KPC was signiﬁ-
cantly higher, at 29.1%, than in the control group, at 19.5%.
This is in line with the results of a recent meta-analysis that
pooled data from 16 studies and showed a signiﬁcantly
increased mortality rate for ESBL-associated bacteraemia [1].
The subset of patients with KPC-producing K. pneumoniae in
our study had an even higher mortality rate, at 47.4%, as
opposed to 27.5% for those with ESBL-producing K. pneumo-
niae. Although the difference was not statistically signiﬁcant,
probably because of the relatively small number of patients,
our data strengthen the previously reported association
between KPC-producing K. pneumoniae bacteraemia and
increased mortality [14].
The independent risk factors for ESBL-associated bactera-
emia included recent antibiotic use, admission from a nursing
home, length of hospital stay prior to infection, chronic renal
failure, presence of a gastrostomy tube, and history of trans-
plant. Recent antibiotic use has been pointed out as an inde-
pendent risk factor in multiple studies that have investigated
ESBL-associated bacteraemia [11,15–18]. Admission from a
nursing home has also been identiﬁed as a risk factor for
ESBL production in several studies investigating bacteraemia
[19–21]. The presence of a gastrostomy tube has been asso-
ciated with acquisition of ESBL-producing organisms among
nursing home residents [22,23], whereas chronic renal failure
has not been associated with acquisition of ESBL-producing
organisms.
Independent risk factors for mortality in the ESBL group
included higher Apache II score at the time of positive blood
culture and inappropriate empirical therapy. The association
of higher Apache II score with increased mortality is not sur-
prising and this was an independent risk factor for mortality
in control cases as well. Inappropriate empirical therapy,
deﬁned by the use of antibiotic(s) that lack in vitro activity
against the causative organism, has been identiﬁed as inde-
pendent risk factor for death in ESBL-associated bacteraemia
in several studies [24,25]. We may therefore speculate that
the signiﬁcantly increased mortality with inappropriate empir-
ical therapy, which occurred more frequently in the ESBL
and KPC groups than in the control group, contributed to
the excess mortality.
Our study has several limitations. First, we analysed ESBL-
producing Enterobacteriaceae together, not by species. The
selection of controls to be in the same proportions by spe-
cies as the cases helped to address some of the potential
bias arising from this. Second, our analysis of the KPC cases
was limited, owing to the relatively small number of cases.
Finally, we were not able to associate types of ESBL with
clinical attributes, because of their heterogeneity.
In conclusion, mortality associated with bacteraemia
caused by ESBL-producing or KPC-producing Enterobacteria-
ceae continues to be high, despite improved detection in the
clinical laboratory. CTX-M-type ESBLs are now common in
E. coli and are also present in other species in the northeast-
ern USA. The frequent occurrence of delay in appropriate
therapy probably contributes to the excess mortality. The
use of antimicrobials with activity against ESBL-producing
organisms, such as carbapenems, is generally accepted as
appropriate in unwell patients with risk factors. However,
the advent of K. pneumoniae producing KPC-type carbape-
nemase further complicates this issue.
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